DRREDDY Dr. Reddy's Laboratories Q1 FY26 results (Apr–Jun 2025) and concall
Dr. Reddy's Laboratories reported a mixed Q1 FY26, with consolidated revenues growing 11% YoY to ₹8,545 crores, despite a 17% decline in US generics. EBITDA margin of 26.7% exceeded the 25% aspiration, though it saw YoY compression due to gross margin pressure and increased SG&A investments. The company made progress in strategic areas like biosimilars and NRT integration, while addressing recent USFDA observations at its Srikakulam facility.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 5,015 | 5,563 | 7,810 |
| EBITDA | 1,192 | 1,443 | 3,837 |
| Net profit | 849 | 1,201 | 2,961 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
